Uncategorized

$6.7m awarded to pancreatic cancer research projects

Published

on

Pancreatic cells

The Stephenson Global Pancreatic Cancer Research Institute (SGPCRI) is awarding $6.7 million to eight projects in 2026. 

The funded projects span the full continuum of pancreatic cancer research, from prevention and early detection to next-generation therapies.  

“Every investment we make is driven by one goal: to urgently end pancreatic cancer,” said A Emmet Stephenson Jr, Co-Founder of SGPCRI. “Our mission is to identify, fund, and accelerate the most innovative research in the field, wherever it exists. By empowering exceptional scientists to pursue transformative ideas, we hope to speed the discoveries that will prevent pancreatic cancer, detect it earlier, and deliver more effective treatments to patients worldwide.” 

The Stephenson Global Pancreatic Cancer Research Institute was established in honour of Toni Lyn Stephenson, who passed away from pancreatic cancer in 2020. Inspired by her legacy, the family made a $150 million commitment, representing approximately two-thirds of the funding currently directed toward pancreatic cancer research, to accelerate the most innovative science. 

“We created SGPCRI to support investigators who are willing to challenge conventional thinking and pursue ideas with the potential to fundamentally change pancreatic cancer outcomes,” said Tessa Stephenson Brand, Co-Founder of SGPCRI. 

Award recipients 

The 2026 Stephenson Global Scholar Grant recipients will include: 

  • Jenn Abelin, Senior Group Leader of the Proteomics Platform at the Broad Institute of MIT and Harvard, and William Freed-Pastor, Assistant Professor of Medicine at Harvard Medical School and physician-scientist at Dana-Farber Cancer Institute: Their work will identify hidden tumour antigens displayed by pancreatic cancer cells to advance next-generation cancer vaccines and T-cell therapies. 
  • Erik Knudsen, Professor of Oncology, Senior Vice President, Associate Director Oo Basic Science Research, and Chair of the Department of Molecular and Cellular Biology at Roswell Park Comprehensive Cancer Center, and Agnieszka Witkiewicz, Professor of Oncology and Director of the Advanced Tissue Imaging Shared Resource at Roswell Park Comprehensive Cancer Center: Their work will target key regulators of cell division to prevent and overcome resistance to RAS-targeted therapies for pancreatic cancer. 
  • Shohei Koide, Professor of Biochemistry and Molecular Pharmacology and Director of Cancer Biologics at NYU Grossman School of Medicine and NYU Perlmutter Cancer Center: His work will advance antibodies targeting the protein LCN2 to help immune cells infiltrate and attack pancreatic tumours. 
  • Leyuan Ma, Assistant Professor in the Department of Pathology and Laboratory Medicine at the Perelman School of Medicine at the University of Pennsylvania and Children’s Hospital of Philadelphia: His work will engineer vaccine-boosted T cells to overcome pancreatic tumours’ immunosuppressive defences and activate the body’s own anti-tumour immune response, with the goal of developing an off-the-shelf immunotherapy. 
  • Cristian Prieto-García, Ramón y Cajal group leader at the Institute of Biomedicine of Seville (IBiS) and the University of Seville, Spain: His work will evaluate next-generation splicing inhibitors designed to exploit a unique vulnerability in pancreatic cancer cells, causing them to accumulate toxic proteins and die while sparing healthy cells. 

The post $6.7m awarded to pancreatic cancer research projects appeared first on Drug Discovery World (DDW).

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version